

October 9, 2018

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Re: Intimation of Settlement by Glenmark Pharmaceuticals Limited (“Company”) of buyback of U.S.\$86.5 million (“Buyback FCCBs”) of its U.S.\$200 million 2 per cent resettable onward starting equity linked securities due 28 June 2022 (“FCC Bonds”)

This is further to our letters dated 1 October 2018 and 3 October 2018, regarding buyback in respect of the FCC Bonds issued in 2016, which are currently listed on the Singapore Exchange Securities Trading Limited.

The Company wishes to announce that the buyback of the Buyback FCCBs was completed on 5 October 2018 and the registrar and transfer agent has cancelled the Buyback FCCBs. Accordingly, the aggregate principal amount of FCC Bonds that remain outstanding as of the date hereof is U.S.\$ 113,500,000.

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)